Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Zev Wainberg, M.D., M.Sc.
Zev Wainberg, M.D., M.Sc.

Specialty:

Hematology/Oncology

General Information:

Gender:
Male
Language(s):
English

Affiliation(s):

Assistant Professor, Department of Medicine, Hematology/Oncology, Gastrointestinal Oncology Program, UCLA/Santa Monica Cancer Center
Director, Early Phase Clinical Research Support (EPCRS)
Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

Santa Monica-UCLA Medical Center and Orthopaedic Hospital
Ronald Reagan UCLA Medical Center

Education:

Fellowship:
Hematology/Oncology, UCLA School of Medicine, 2003 - 2006
Residency:
Internal Medicine, Montefiore Medical Center Moses Division Hospital, 2001 - 2003
Internship:
Internal Medicine, Montefiore Medical Center Moses Division Hospital, 2000 - 2001
Medical Degree:
M.D., Tel Aviv University Sackler School of Medicine, 2000

Certification(s):

Medical Board Certification(s):
Internal Medicine, American Board of Internal Medicine, 2003

Contact Information:

Phone:
(310) 829-5471
Fax:
(310) 825-1877
Email:

Practice Information:

Clinical Interest(s):
Biliary
Cancers Of The Digestive Tract
General Hematology
General Oncology

Scientific Interest(s):

Dr. Zev Wainberg's clinical interests include designing GI (gastroenterology) cancer clinical trials. He is particularly interested in the development and testing of new targeted therapies for the treatment of colon cancer, gastric cancer and esophagus cancer.

Wainberg's laboratory and translational research involves gene expression patterns in a variety of GI cancers and the molecular profiling of these cancers for novel therapies. His research also involves the targeting of GI and prostate cancers with new antibody technologies.

Selected Cancer-Related Publications:

Wainberg ZA, Lin LS, DiCarlo B, Dao KM, Patel R, Park DJ, Wang HJ, Elashoff R, Ryba N, Hecht JR. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br J Cancer. 2011 Sep 6;105(6):760-5. Epub 2011 Aug 2

Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA, Reiter RE. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med. 2010 Dec;16(12):1414-20. Epub 2010 Nov 7

Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ, Finn RS. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res. 2010 Mar 1;16(5):1509-19. Epub 2010 Feb 23

Bilchik A, Nissan A, Wainberg Z, Shen P, McCarter M, Protic M, Howard R, Elashoff D, Tyler J, Peoples GE, Stojadinovic A. Surgical quality and nodal ultrastaging is associated with long-term disease-free survival in early colorectal cancer: an analysis of 2 international multicenter prospective trials. Ann Surg. 2010 Sep;252(3):467-74; discussion 474-6.